Le Lézard
Classified in: Health
Subjects: HEALTH, MISCELLANEOUS, MISCELLANEOUS, MISCELLANEOUS

Tech-facilitated gender-based violence is an international, human rights concern, finds new research


San José, Costa Rica, June 08, 2023 (GLOBE NEWSWIRE) -- A report released today by the Centre for International Governance Innovation (CIGI) at the 12th RightsCon summit in Costa Rica reveals that almost 25% of people who experience online harm feel they are targeted due to their gender identity. It says the most prevalent, frequent and severe experiences of online harm occur among transgender and gender-diverse people.

The report, Supporting Safer Digital Spaces, analyzes data from the first statistically meaningful survey of women's and LGBTQ+ individuals' online experiences focused on the Global South. It covers 18,000 respondents of all genders in 18 countries.

Key findings include:

Online harms, which are forms of technology-facilitated violence (TFV), can range from impersonation to doxing, from physical threats to the non-consensual distribution of intimate images and deliberate personal attacks on communications channels. Even after serious incidents of TFV, many people do not seek help ? the survey found that 40% of participants did not reach out to anyone after experiencing online harm.

"Due to increased sexism, homophobia, transphobia and violent threats online, many women and LGBTQ+ people are having to choose between facing the abuse that comes with being a woman or LGBTQ+ online or being silent. This abusive behaviour leads to real harms in both the digital and physical world and there are few supports available to people targeted by TFV," said CIGI Senior Fellow Suzie Dunn, lead author of the report, which details 87 recommendations to address technology-facilitated violence through educational campaigns, legal and policy resources, tools for support and non-governmental resources.

"Right to life and liberty and right to freedom of opinion and expression are basic human rights," said Anja Kovacs, an independent researcher and consultant on internet and data governance from a feminist perspective, who advised CIGI. "TFV steals these rights from women, LGBTQ+ people and equity-seeking groups. Governments, technology companies, civil society organizations, researchers, academics and think tanks must work together to eradicate TFV."

The 18 countries surveyed by global market research firm Ipsos, with funding from Canada's International Research Development Centre, are Algeria, Argentina, Brazil, Canada, Chile, China, Colombia, Ecuador, France, Germany, India, Jordan, Kenya, Saudi Arabia, South Africa, Tunisia, the United Arab Emirates and the United States.

To read the report and access individual country results from the survey, please visit: cigionline.org/safer-internet.

- 30 -

Attachment



These press releases may also interest you

at 18:05
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 14:06
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: